These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 24318989)
1. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989 [TBL] [Abstract][Full Text] [Related]
2. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599 [TBL] [Abstract][Full Text] [Related]
3. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Liu L; Li CH; Jin TF; Xu DY Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763 [TBL] [Abstract][Full Text] [Related]
4. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population. Li J; Zuo X; Lv X; Kong F; Xu W; Yang S Tumour Biol; 2014 Aug; 35(8):7569-74. PubMed ID: 24793015 [TBL] [Abstract][Full Text] [Related]
5. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer. Chen ZH; Wang L; Luo LP Genet Mol Res; 2014 Sep; 13(3):7484-91. PubMed ID: 25222248 [TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population. Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975 [TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Sun Y; Wu Y; Li W; Kong Z; Zou X Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355 [TBL] [Abstract][Full Text] [Related]
8. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients. Zhong G; Li HK; Shan T; Zhang N Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis. Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935 [TBL] [Abstract][Full Text] [Related]
11. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. Gao H; Ge RC; Liu HY; Wang Y; Yan S Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer. Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228 [TBL] [Abstract][Full Text] [Related]
13. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563 [TBL] [Abstract][Full Text] [Related]
14. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer. Bai Y; Wang L; Li G; Fang X; Li Y; Yang S Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434 [TBL] [Abstract][Full Text] [Related]
16. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659 [TBL] [Abstract][Full Text] [Related]
17. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858 [TBL] [Abstract][Full Text] [Related]
18. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265 [TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer. Shi ZH; Shi GY; Liu LG Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829 [TBL] [Abstract][Full Text] [Related]
20. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]